Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.63 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.52 |
| ▸ | MTOR | P42345 | 5/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12929015 | 0.92 | PIK3CA (0.63) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL13977044 | 0.89 | PIK3CD (0.54) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL13967603 | 0.88 | PIK3CA (0.67) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL13976851 | 0.87 | PIK3CA (0.54) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL13977045 | 0.87 | PIK3CA (0.64) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL13967598 | 0.85 | PIK3CA (0.51) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL18995708 | 0.85 | PIK3CA (0.64) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL14684666 | 0.84 | PIK3CA (0.59) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL12929009 | 0.81 | PIK3CA (0.77) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL13976849 | 0.79 | PIK3CA (0.51) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2019-11-21 | — | — | US | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| US-9295673-B2 | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150320727-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC | 2015-11-12 | — | — | US | disclosed |
| US-9085560-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150087627-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC | 2015-01-29 | — | — | US | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 14/4885PIK3CD 2/4885 |
| US-20150030588-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | PIK3C3, ERBB3, ERBB2 | PIK3CA 7/4885PIK3R1 94/4885PIK3CD 58/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 14/4885PIK3CD 2/4885 |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 14/4885PIK3CD 2/4885 |
| US-20150087627-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, PIK3CA, AKT1 | PIK3CA 2/4885PIK3R1 36/4885PIK3CD 13/4885 |
| US-20150320727-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 14/4885PIK3CD 2/4885 |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 14/4885PIK3CD 2/4885 |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | MTOR, RPTOR, RICTOR | PIK3CA 4/4885PIK3R1 33/4885PIK3CD 14/4885 |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 14/4885PIK3CD 2/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | PIK3CA 6/4885PIK3R1 75/4885PIK3CD 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.